SG/PUT/BRISTOL-MYERS SQUIBB/40/0.1/21.03.25

SG/PUT/BRISTOL-MYERS SQUIBB/40/0.1/21.03.25 Stock

DE000SU6Q1X0

Market Closed - Boerse Frankfurt Warrants 15:46:11 2024-06-14 EDT
0.31 ^EUR	+3.33%

Current month	-8.82%
1 month	+47.62%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BRISTOL-MYERS SQUIBB COMPANY

Chart SG/PUT/BRISTOL-MYERS SQUIBB/40/0.1/21.03.25

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Bristol Myers: FDA approval for treatment	06-14	CF
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors	06-13	MT
Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval	06-13	DJ
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors	06-13	BU

More news

Quotes 5-day view

Date	Price	Change
24-06-14	0.31	+3.33%
24-06-13	0.3	+15.38%
24-06-12	0.26	+4.00%
24-06-11	0.25	-3.85%
24-06-10	0.26	-13.33%

Real-time Boerse Frankfurt Warrants

Last update June 14, 2024 at 03:46 pm

More quotes

Static data

Product type	Warrants
Buy / Sell	PUT
Underlying	BRISTOL-MYERS SQUIBB COMPANY
Issuer	Société Générale
WKN	SU6Q1X
ISIN	DE000SU6Q1X0
Date issued	2024-01-08
Strike	40 $
Maturity	2025-03-21 (279 Days)
Parity	10 : 1
Emission price	0.19 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	0.36 €
Lowest since issue	0.086 €
Delta	-0.39x
Omega	4.806
Premium	11.1x
Gearing	12.22x
Moneyness	0.9709
Difference Strike	-1.2 $
Difference Strike %	-3.00%
Spread	0.01 €
Spread %	3.13%
Theoretical value	0.3150
Implied Volatility	28.47 %
Total Loss Probability	49.54 %
Intrinsic value	0.000000
Present value	0.3150
Break even	36.63 €
Theta	-0x
Vega	0.01x
Rho	-0.01x

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

More about the company